SLC5A2 and heart failure: It should also be noted that SGLT2 inhibitors have variable selectivity for SGLT2 vs. SGLT1, i.e., 2500× selectivity for empagliflozin, 1200× selectivity for dapagliflozin, 250× selectivity for canagliflozin, and 20x selectivity for sotagliflozin [82], and less selective SGLT2 inhibitors was associated with a lower risk of heart failure in network meta-analyses [83, 84].